A class action lawsuit has been filed against Zoetis Inc. alleging the company misled investors about the strength of its Companion Animal segment. The lawsuit claims Zoetis portrayed this segment as a strong growth driver while hiding safety concerns, rising competition, and declining veterinarian confidence that hurt sales and outlook. The truth emerged through disclosures from August 2025 to May 2026, culminating in a sharp stock price drop of 21.5% after poor Q1 2026 results and lowered guidance. Investors who bought Zoetis shares between January 2025 and May 2026 are encouraged to contact the law firm before the July 27, 2026 deadline to participate in the case.
A class action lawsuit has been filed against Zoetis Inc. for allegedly misleading investors about the performance of its main animal health products, including Librela, Simparica Trio, Apoquel, and Cytopoint. The complaint claims Zoetis failed to di...
Zoetis Inc. reported flat net income of $601 million for Q1 2026 but lowered its full-year profit guidance due to weaker demand and increased price sensitivity among pet owners. Following this announcement, Zoetis's stock price fell sharply by 21.5%....
